CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleMarket cap is $1.89B, above the global median of $1.15B
- FinancialsHigh structural barrier to entry
- Interpretations10 currently firing — 10
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
2.67TKRW1.89B · vs all stocks (USD)
Trailing P/E
18.91xvs Biotechnology peers
Revenue (TTM)
451.93BKRW319.98M · vs all stocks (USD)
Profit Margin
33.43%vs Biotechnology peers
Beta
0.5330xvs all stocks
52-Week Change
-19.80%vs all stocks
Market Capitalization
2.67TKRW1.89B · vs all stocks (USD)
Enterprise Value
2.49TKRW1.76B · vs all stocks (USD)
Trailing P/E
18.91xvs Biotechnology peers
Forward P/E
13.97xvs Biotechnology peers
PEG Ratio
0.5475xvs Biotechnology peers
Price to Sales (TTM)
5.89xvs Biotechnology peers
Price to Book (MRQ)
2.58xvs Biotechnology peers
Enterprise to Revenue
5.85xvs Biotechnology peers
Enterprise to EBITDA
10.81xvs Biotechnology peers
Gross Margin
77.23%vs Biotechnology peers
Profit Margin
33.43%vs Biotechnology peers
Operating Margin
40.68%vs Biotechnology peers
Return on Assets (TTM)
12.43%vs Biotechnology peers
Return on Equity (TTM)
16.38%vs Biotechnology peers
Revenue (TTM)
451.93BKRW319.98M · vs all stocks (USD)
Revenue per Share (TTM)
41.86KKRWUpdated Aug 19, 2026Quarterly Revenue Growth
25.10%vs Biotechnology peers
Gross Profit (TTM)
354.55BKRW251.03M · vs all stocks (USD)
EBITDA (TTM)
245.05BKRW173.51M · vs all stocks (USD)
Net Income (TTM)
151.06BKRW106.96M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
18.90%vs Biotechnology peers
Operating Cash Flow (TTM)
166.88BKRW118.16M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
95.62BKRW67.70M · vs all stocks (USD)
Payout Ratio
0.00%vs Biotechnology peers
Minority Interest (Equity)
29.90BKRWFY2025 · Dec 31, 2025Revenue
425.11BKRWFY2025 · Dec 31, 2025Cost of Goods Sold
91.63BKRWFY2025 · Dec 31, 2025Gross Profit
333.48BKRWFY2025 · Dec 31, 2025Operating Income
200.85BKRW142.21M · vs all stocks (USD)
Pre-tax Income
196.75BKRWFY2025 · Dec 31, 2025Income Tax Expense
49.78BKRWFY2025 · Dec 31, 2025Net Income
146.97BKRWFY2025 · Dec 31, 2025EBIT
197.88BKRWFY2025 · Dec 31, 2025EBITDA (Income Statement)
230.21BKRWFY2025 · Dec 31, 2025Research & Development
11.70BKRWFY2025 · Dec 31, 2025Selling, General & Administrative
63.86BKRWFY2025 · Dec 31, 2025Other Operating Expenses
395.61MKRWFY2025 · Dec 31, 2025Non-operating Interest Income
12.64BKRWFY2025 · Dec 31, 2025Non-operating Interest Expense
1.13BKRWFY2025 · Dec 31, 2025Net Income from Continuing Operations
146.97BKRWFY2025 · Dec 31, 2025Minority Interests (P&L)
-6.10BKRWFY2025 · Dec 31, 2025Operating Cash Flow
105.10BKRWFY2025 · Dec 31, 2025Free Cash Flow
91.87BKRWFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
209.70BKRWFY2025 · Dec 31, 2025Starting Profit (CF Statement)
146.97BKRWFY2025 · Dec 31, 2025Stock-based Compensation
7.42BKRWFY2025 · Dec 31, 2025Other Non-cash Items
-9.89BKRWFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-22.89BKRWFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-16.52BKRWFY2025 · Dec 31, 2025Capital Expenditures
-13.23BKRWFY2025 · Dec 31, 2025Net Intangibles (CF)
-16.13BKRWFY2025 · Dec 31, 2025Purchase of Investments
-565.77BKRWFY2025 · Dec 31, 2025Sale of Investments
546.67BKRWFY2025 · Dec 31, 2025Other Investing Activity
-159.78MKRWFY2025 · Dec 31, 2025Net Investing Cash Flow
-32.50BKRWFY2025 · Dec 31, 2025Common Stock Repurchase
-1.32BKRWFY2025 · Dec 31, 2025Other Financing Charges
-23.87BKRWFY2025 · Dec 31, 2025Net Financing Cash Flow
-19.23BKRWFY2025 · Dec 31, 2025Shares Outstanding
10.80MSharesUpdated Aug 19, 2026Float Shares
5.18MSharesUpdated Aug 19, 2026% Held by Insiders
42.79%vs all stocks
% Held by Institutions
23.08%vs all stocks
Total Cash (MRQ)
249.30BKRW176.51M · vs all stocks (USD)
Total Cash per Share (MRQ)
23.08KKRWUpdated Aug 19, 2026Total Debt (MRQ)
28.56BKRW20.22M · vs all stocks (USD)
Current Ratio (MRQ)
7.50xvs Biotechnology peers
Book Value per Share (MRQ)
95.77KKRWUpdated Aug 19, 2026Total Assets
1.08TKRW762.44M · vs all stocks (USD)
Total Current Assets
679.37BKRWFY2025 · Dec 31, 2025Total Liabilities
96.68BKRWFY2025 · Dec 31, 2025Total Non-current Assets
397.47BKRWFY2025 · Dec 31, 2025Total Non-current Liabilities
3.63BKRWFY2025 · Dec 31, 2025Total Current Liabilities
93.05BKRWFY2025 · Dec 31, 2025Cash
209.70BKRWFY2025 · Dec 31, 2025Cash & Cash Equivalents
209.70BKRWFY2025 · Dec 31, 2025Other Short-term Investments
329.07BKRWFY2025 · Dec 31, 2025Accounts Receivable
74.99BKRWFY2025 · Dec 31, 2025Inventory
55.85BKRWFY2025 · Dec 31, 2025Accounts Payable
5.99BKRWFY2025 · Dec 31, 2025Short-term Debt
28.38BKRWFY2025 · Dec 31, 2025Other Current Liabilities
520.94MKRWFY2025 · Dec 31, 2025Long-term Debt
751.25MKRWFY2025 · Dec 31, 2025Other Non-current Liabilities
400.00KRWFY2025 · Dec 31, 2025Common Stock (Book)
6.59BKRWFY2025 · Dec 31, 2025Retained Earnings
1.16TKRWFY2025 · Dec 31, 2025Total Shareholders' Equity
980.16BKRW693.99M · vs all stocks (USD)
Treasury Stock
268.81BKRWFY2025 · Dec 31, 202552-Week Low
208.50KKRWUpdated Aug 19, 202652-Week High
342.00KKRWUpdated Aug 19, 202652-Week Change
-19.80%vs all stocks
Beta
0.5330xvs all stocks
50-Day MA
248.42KKRWUpdated Aug 19, 2026200-Day MA
248.56KKRWUpdated Aug 19, 2026Avg 10-Day Volume
67.54KSharesUpdated Aug 19, 2026Avg 30-Day Volume
53.52KSharesUpdated Aug 19, 2026Diluted EPS (TTM)
12.82KKRWUpdated Aug 19, 202610 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
MRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total Liabilities
Cash covers most of its debt, with earnings high against its liabilities.
Reads
How does this company use capital?
Cash Backing With Revenue And Income Streaks
Revenue has risen in each of three years, profit in all three, and it holds more cash than debt.
Reads
Cash-Flow Ratios Elevated
More of its sales turn into cash than in its industry, and less of that cash is consumed by reinvestment than at most of its peers.
Reads
Three Margin Ratios Elevated Across Gross, Operating, And Cash-Conversion Levels
Its gross margin and its cash margin are high for its industry, and its operating margin is high outright.
Reads
Industry-Benchmarked ROA and Margin Elevated
Returns and margins have sat in the top of its industry across five years.
Reads
Three Margin Ratios Elevated Across Gross, Operating, And Net Levels
Its gross and net margins are high for its industry, and its operating margin is high outright.
Reads
ROE, ROA, And Operating ROA Elevated
It earns more on its equity than its industry does, and on its assets too — not on borrowing alone.
Reads
Is this company growing?
Multi-Year Revenue, Profit, And Income Growth
Revenue has risen in each of three years, gross profit in each of four, and it has made a profit in all five.
Reads
Revenue Growth With Elevated Margin
Revenue up in each of five years, while its operating margin stays high.
Reads
How is this stock valued?
High Retained Earnings With Profitability And Equity
Profits kept in the business fund much of what it owns, after five straight profitable years.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
High structural barrier to entryNotable
Barrier to Entry: 0.65
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $1.89B, above the global median of $1.15BNotable
Market cap (USD): 1,889,343,228.317Global Median: 1,146,734,693.424
Levered free cash flow is $67.7M, above the global median of $16.24MNotable
Levered free cash flow (USD): 67,701,182.296Global Median: 16,239,329.704
Companies that share the same coordination system — how they create, deliver, or capture value.
Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Amylyx Pharmaceuticals, Inc. Common Stock
Tier 1ProductionApproval-Gated PipelineRule
AbCellera Biologics Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Nanjing Vazyme Biotech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
UFP Technologies Inc.
Tier 1ProductionApproval-Gated PipelineRule
Tyra Biosciences, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Zenas BioPharma, Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Fagron NV
Tier 1ProductionApproval-Gated PipelineFlowRule
Jafron Biomedical Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Yifan Pharmaceutical Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Companies that share active interpretations — structural patterns currently present in both stocks.
Games Workshop Group PLC
10 interpretationsThree Margin Ratios Elevated Across Gross, Operating, And Cash-Conversion LevelsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesHigh Retained Earnings With Profitability And EquityCash Backing With Revenue And Income StreaksROE, ROA, And Operating ROA ElevatedCash-Flow Ratios ElevatedMulti-Year Revenue, Profit, And Income GrowthRevenue Growth With Elevated MarginIndustry-Benchmarked ROA and Margin ElevatedThree Margin Ratios Elevated Across Gross, Operating, And Net Levels
United States Lime & Minerals Inc.
10 interpretationsThree Margin Ratios Elevated Across Gross, Operating, And Cash-Conversion LevelsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesHigh Retained Earnings With Profitability And EquityCash Backing With Revenue And Income StreaksROE, ROA, And Operating ROA ElevatedCash-Flow Ratios ElevatedMulti-Year Revenue, Profit, And Income GrowthRevenue Growth With Elevated MarginIndustry-Benchmarked ROA and Margin ElevatedThree Margin Ratios Elevated Across Gross, Operating, And Net Levels
Catalyst Pharmaceuticals Inc.
10 interpretationsThree Margin Ratios Elevated Across Gross, Operating, And Cash-Conversion LevelsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesHigh Retained Earnings With Profitability And EquityCash Backing With Revenue And Income StreaksROE, ROA, And Operating ROA ElevatedCash-Flow Ratios ElevatedMulti-Year Revenue, Profit, And Income GrowthRevenue Growth With Elevated MarginIndustry-Benchmarked ROA and Margin ElevatedThree Margin Ratios Elevated Across Gross, Operating, And Net Levels